Pulmatrix, a clinical stage biopharmaceutical company, has announced that it has entered into an agreement with Mylan NV for PUR0200, a clinical stage bronchodilator therapy being studied for COPD. PUR0200 is the first small molecule formulation from the company’s iSPERSE inhaled dry powder technology and is under development as a once-daily therapy in a capsule-based dry powder inhaler (DPI), according to a Pulmatrix news release.
PUR0200 contains a long-acting muscarinic agent (LAMA) being studied for the treatment of COPD and current clinical development is focused on pharmacokinetic bioequivalence in Europe, as indicated on the Pulmatrix news release.
Robert Clarke, CEO of Pulmatrix, states, “Our agreement with Mylan for the development of PUR0200 is a major step for Pulmatrix and the continued development of our iSPERSE technology. At the current stage of development of PUR0200 and goals of the program, Mylan is the ideal partner to bring this product forward for COPD patients.”
Under the terms of the agreement, Pulmatrix will lead the development of work and pharmacokinetic clinical study with collaborative support from Mylan, according to Pulmatrix. Mylan has retained an option for PUR0200 ex-US based on successful completion of the clinical study.
Rajiv Malik, Mylan president, says, “Mylan is excited to partner with Pulmatrix on this potential generic LAMA DPI opportunity. This collaboration demonstrates our continued commitment to building our global respiratory pipeline, a key strategic growth driver for the company.”